Soiken Holdings Inc. AI Stock Analysis
Want to see JP:2385 full AI Analyst Report?
Soiken Holdings Inc. (2385) AI Stock Analysis
Soiken Holdings Inc.
(TSE/TYO:2385)
Soiken Holdings scores below average, driven primarily by a steep multi-year revenue contraction of nearly 60% and two consecutive years of losses, only partially offset by a projected return to profitability in FY2026. The key strength is an exceptionally conservative, debt-free balance sheet with a large equity cushion that provides resilience and time to execute a turnaround, alongside recovering free cash flow. Technicals are neutral, with the price above short-term moving averages but still beneath the 100- and 200-day lines, signalling a longer-term downtrend that has yet to reverse. Valuation is a modest drag, as a P/E of 27.5 looks demanding against shrinking revenue, though the 4.48% dividend yield offers meaningful income support. Investors should look for evidence of revenue stabilisation and sustained profitability before the outlook improves materially.
Soiken Holdings Inc. (2385) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 5.52B
- Dividend Yield
- 4.74%
- Average Volume (3M)
- 290.25K
- Price to Earnings (P/E)
- 32.6
- Beta (1Y)
- 0.93
- Revenue Growth
- -33.44%
- EPS Growth
- 3.65%
- Country
- Japan
- Employees
- 45
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Soiken Holdings Inc. Business Overview & Revenue Model
Company Description
Founded in 1994 and headquartered in Toyonaka, Japan, Soiken Holdings Inc. primarily focuses on the advancement of biomarkers. The company’s operations span a diverse range of health and wellness sectors. It is actively involved in the creation and c...
Soiken Holdings Inc. Financial Statement Overview
Summary
Financial results are mixed and lean negative. Revenue has collapsed roughly 59% from ¥9.35bn in FY2022 to an estimated ¥3.87bn in FY2026, including a projected -20% decline in FY2026 alone, and the company posted operating and net losses in FY2024 and FY2025 (income statement score 30). The standout strength is a debt-free balance sheet with ~89% equity-to-assets and stable equity of ¥6–7bn, offering strong downside protection, though ROE remains thin at a projected 3.5% (balance sheet score 75). Cash flow has been erratic, swinging from ¥2.14bn operating cash flow in FY2022 to -¥881m in FY2024 before recovering to ¥558m in FY2025 and a projected ¥415m in FY2026 (cash flow score 45). The projected return to profitability and positive free cash flow are encouraging, but on a much smaller revenue base that raises questions about structural competitiveness.
Income Statement
30NegativeBalance Sheet
75PositiveCash Flow
45Neutral| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.85B | 3.87B | 4.85B | 5.16B | 8.08B | 9.35B |
| Gross Profit | 2.41B | 1.87B | 2.41B | 2.48B | 3.72B | 4.26B |
| EBITDA | -192.48M | 287.51M | -201.93M | -583.21M | 750.07M | 1.23B |
| Net Income | -210.41M | 212.29M | -210.70M | -662.20M | 451.85M | 809.71M |
Balance Sheet | ||||||
| Total Assets | 6.81B | 6.85B | 6.81B | 6.96B | 8.24B | 8.49B |
| Cash, Cash Equivalents and Short-Term Investments | 5.26B | 5.65B | 5.26B | 4.79B | 5.95B | 6.22B |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 775.16M | 742.48M | 775.16M | 708.58M | 1.07B | 1.64B |
| Stockholders Equity | 6.02B | 6.11B | 6.02B | 6.23B | 6.97B | 6.65B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 377.20M | 521.19M | -895.42M | -141.08M | 2.09B |
| Operating Cash Flow | 0 | 415.15M | 557.96M | -880.82M | -101.55M | 2.14B |
| Investing Cash Flow | 0 | 119.10M | -389.41M | -14.29M | 160.37M | -244.58M |
| Financing Cash Flow | 0 | -139.80M | -214.00K | -260.71M | -130.21M | -129.94M |
Soiken Holdings Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2385, the sentiment is Neutral. The current price of 211.00 is below the 20-day moving average (MA) of 211.55, below the 50-day MA of 216.08, and below the 200-day MA of 228.58, indicating a bearish trend. The MACD of -3.62 indicates Positive momentum. The RSI at 49.46 is Neutral, neither overbought nor oversold. The STOCH value of 56.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:2385.
Soiken Holdings Inc. Peers Comparison
Overall Rating
JP:489156Neutral- JP:238551Neutral
JP:218350Neutral
JP:234244Neutral
JP:206A41Neutral
JP:237040Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:4891 | 56Neutral | JPY 6.49B | -6.18 | ― | ― | ― | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| JP:2385 | 51Neutral | JPY 5.52B | 32.56 | ― | 4.74% | -33.44% | 3.65% |
| JP:2183 | 50Neutral | JPY 4.38B | -1.16 | ― | 4.12% | -21.55% | -497.97% |
| JP:2342 | 44Neutral | JPY 3.42B | 105.84 | ― | ― | 8.53% | 97.93% |
| JP:206A | 41Neutral | JPY 3.96B | -4.51 | ― | ― | 84.23% | 33.14% |
| JP:2370 | 40Underperform | JPY 4.84B | -4.19 | ― | ― | 1.41% | 1.12% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:2385 | Soiken Holdings Inc. | 211.00 | -10.57 | -4.77% | |
| JP:2183 | Linical Co., Ltd. | 194.00 | -99.92 | -34.00% | |
| JP:2342 | Trans Genic Inc. | 203.00 | 6.00 | 3.05% | |
| JP:2370 | MEDINET Co., Ltd. | 17.00 | -14.00 | -45.16% | |
| JP:4891 | TMS Co., Ltd. | 134.00 | -7.00 | -4.96% | |
| JP:206A | PRISM BioLab Co. LTD | 107.00 | -94.00 | -46.77% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 26, 2026